The Pharma Data

MARCH 31, 2022

Bayer announced today that it is strengthening the production network of its pharmaceutical division to ensure sustainable competitiveness and support the transformation of its pharmaceutical business based on breakthrough innovation delivering long-term, sustainable business growth.

Production 52

Production Pharmaceuticals Science Therapies 52

DrugBank

MARCH 7, 2024

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. adults using obesity medications by 2030, further underlining the growing significance of this sector. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

DrugBank

MARCH 15, 2024

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. Eli Lilly's Triumph: Pioneering Solutions in Weight Management Eli Lilly's remarkable achievement with its drug Mounjaro (tirzepatide) in the fourth quarter of 2023 has sent ripples of excitement through the pharmaceutical industry.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

DrugBank

NOVEMBER 4, 2024

The pharmaceutical industry is the primary source of antibiotic innovation; therefore, it must lead the way in combating resistance.   trillion loss in GDP by 2030 shows the urgency of this crisis.    Pharmaceutical companies are, therefore, exploring innovative approaches.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

Drug Target Review

NOVEMBER 15, 2023

The generational shift as Gen-Z enter and move up the workforce, who are expected to comprise 58 percent of the global workforce by 2030, is accelerating the introduction of these new technologies. Nick is a highly experienced commercial leader with more than 20 years in the pharmaceutical and biotechnology industries.

Pharmacokinetics 105

Pharmacokinetics International Laboratories Drugs 105

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

Codon

NOVEMBER 3, 2024

But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. But now, researchers are increasingly using machine learning to speed up pharmaceutical breakthroughs.

Vaccine 100

Vaccine Trials Therapies Treatment 100

The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. In terms of energy management, all Sanofi sites will use 100% renewable electricity and the company has set a target of a carbon-neutral car fleet , both by 2030.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

MAY 15, 2023

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule Teva Pharmaceutical Industries Ltd. billion to hold us to our environmental and social targets—making Teva the largest SLB issuer in the pharmaceutical industry.

Government 40

Government Pharmaceuticals Compliance Production 40

The Pharma Data

OCTOBER 9, 2021

Improvement Rectifier Designation is designed to accelerate the development and review of pharmaceuticals intended to treat serious or life- menacing conditions with prelusive testimonial that indicates they may demonstrate a substantial enhancement over available rectifiers that have entered full FDA imprimatur. trillion per space by 2030.

Disease 52

Disease FDA Therapies Trials 52

The Pharma Data

OCTOBER 14, 2021

Alzheimer’s is the most common form of dementia, which currently affects more than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per year by 2030. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Therapies 52

Therapies Disease FDA Trials 52

New Drug Approvals

JANUARY 31, 2024

The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. At Premier Consulting, our team of pharmaceutical regulatory experts is helping clients understand the changing regulatory landscape related to ophthalmic drugs and devices. The global ophthalmic drugs market size was valued at $33.81

FDA 52

FDA Packaging Regulations Compliance 52

The Pharma Data

DECEMBER 1, 2020

Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 was endorsed by the Seventy-third World Health Assembly last week. She said achieving the 2030 goals will happen only with collaboration and coordination across sectors, with strong country ownership.

Disease 52

Disease Vaccine Government Science 52

Drug Target Review

OCTOBER 1, 2024

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Being a doctor means giving courage and hope day in, day out to those experiencing illness.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Vial

MAY 20, 2024

Within each of these, pharmaceutical and biotech sponsors are supported by preclinical and clinical contract research organizations (CROs) in clinical trials across various indications. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

MARCH 11, 2021

And at Pharmaceuticals, we are seeing success in our late-stage pipeline and are very well positioned with the investments we are making in our future. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. through 2023.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

MAY 18, 2021

Sales at Pharmaceuticals were steady, and in the Consumer Health Division we performed better than the competition.” Pharmaceuticals: significant advances for Xarelto™ and Eylea™. EBITDA before special items at Pharmaceuticals declined by 6.0 The company confirmed the full-year outlook it issued in February 2021.

Science 40

Science Pharmaceuticals Production Marketing 40

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

MARCH 2, 2021

ii It is projected that by 2030, close to half of the U.S. As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JANUARY 26, 2021

The patent enters into force on 27 January 2021 and expires in 2030. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. and are linked to the company’s project AD1503.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

Vial

APRIL 18, 2024

from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 billion in 2022, anticipates steady growth at a compound annual growth rate (CAGR) of 6.6% Additionally, the ophthalmic drugs market, valued at USD 33.81

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

The Pharma Data

AUGUST 5, 2021

percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

FEBRUARY 24, 2022

with more than 8 million cases expected by 2030. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. . – FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. from 2024 to 2030. These services range from clinical study design and data management to statistical analysis and regulatory support.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

SEPTEMBER 15, 2020

The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

The Pharma Data

NOVEMBER 22, 2020

About EZEPROGIND (AZP2006): Alzprotect is developing a drug candidate, EZEPROGIND, whose mode of action, acting on Progranulin secretion, is clearly different from other products developed in the past 15 years by the pharmaceutical industry. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030. How do CROs solve the challenges of managing clinical trials?

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. Between the technical uncertainty and the horrendous PR, pharmaceutical companies had little interest in adopting molecular farming technologies. The total global bioprocessing capacity was estimated at 17.4

Engineering 87

Engineering Vaccine Production RNA 87

Agency IQ

NOVEMBER 20, 2023

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has suggested that replacing certain paper product information with electronic versions has benefits for healthcare providers, regulatory agencies and patients. Realistically, paper product information could be phased out by 2030.

Production 40

Production Packaging Hospitals Regulations 40

The Pharma Data

MAY 4, 2021

.” The arrangement is part of Lilly ‘s philanthropic efforts and supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030. We call this global effort Lilly 30×30.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. An example: For GSPR 12 on devices that incorporate medicinal products, rather than citing the European pharmaceutical regulations (Directive 2001/83/EC), the U.K. government continued to recognize CE-marked products for a limited time.

Regulations 40

Regulations International Production Government 40

The Pharma Data

NOVEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. In August 2020 , the Company issued and sold $1.250 billion aggregate principal amount of 1.750% senior unsecured notes due 2030 and $750 million aggregate principal amount of 2.800% senior unsecured notes due 2050. About Regeneron Pharmaceuticals, Inc. REGENERON PHARMACEUTICALS, INC.

Production 40

Production Trials FDA FDA Approval 40

Agency IQ

MARCH 15, 2024

California implements a variety of extended producer responsibility (EPR), programs, including programs to address paint, carpet, mattress, pharmaceutical and battery waste. That amount will increase to 40% in 2030 and 65% in 2032. Improving recycling: SB 54 contains a set of recycling targets that increase between 2028 and 2032.

Regulations 40

Regulations Packaging Compliance Production 40